195 related articles for article (PubMed ID: 11123976)
1. Anthracycline metabolism and toxicity in human myocardium: comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with a reduced level of formation and [4Fe-4S] reactivity of its secondary alcohol metabolite.
Minotti G; Licata S; Saponiero A; Menna P; Calafiore AM; Di Giammarco G; Liberi G; Animati F; Cipollone A; Manzini S; Maggi CA
Chem Res Toxicol; 2000 Dec; 13(12):1336-41. PubMed ID: 11123976
[TBL] [Abstract][Full Text] [Related]
2. Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity.
Sacco G; Giampietro R; Salvatorelli E; Menna P; Bertani N; Graiani G; Animati F; Goso C; Maggi CA; Manzini S; Minotti G
Br J Pharmacol; 2003 Jun; 139(3):641-51. PubMed ID: 12788824
[TBL] [Abstract][Full Text] [Related]
3. Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines. Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity.
Minotti G; Cavaliere AF; Mordente A; Rossi M; Schiavello R; Zamparelli R; Possati G
J Clin Invest; 1995 Apr; 95(4):1595-605. PubMed ID: 7706466
[TBL] [Abstract][Full Text] [Related]
4. Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue.
Minotti G; Parlani M; Salvatorelli E; Menna P; Cipollone A; Animati F; Maggi CA; Manzini S
Br J Pharmacol; 2001 Nov; 134(6):1271-8. PubMed ID: 11704647
[TBL] [Abstract][Full Text] [Related]
5. The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory protein-1 in cytosolic fractions from human myocardium.
Minotti G; Recalcati S; Mordente A; Liberi G; Calafiore AM; Mancuso C; Preziosi P; Cairo G
FASEB J; 1998 May; 12(7):541-52. PubMed ID: 9576481
[TBL] [Abstract][Full Text] [Related]
6. Doxorubicin metabolism and toxicity in human myocardium: role of cytoplasmic deglycosidation and carbonyl reduction.
Licata S; Saponiero A; Mordente A; Minotti G
Chem Res Toxicol; 2000 May; 13(5):414-20. PubMed ID: 10813659
[TBL] [Abstract][Full Text] [Related]
7. Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy.
Minotti G; Ronchi R; Salvatorelli E; Menna P; Cairo G
Cancer Res; 2001 Dec; 61(23):8422-8. PubMed ID: 11731422
[TBL] [Abstract][Full Text] [Related]
8. Defective taxane stimulation of epirubicinol formation in the human heart: insight into the cardiac tolerability of epirubicin-taxane chemotherapies.
Salvatorelli E; Menna P; Gianni L; Minotti G
J Pharmacol Exp Ther; 2007 Feb; 320(2):790-800. PubMed ID: 17135345
[TBL] [Abstract][Full Text] [Related]
9. Anthracycline secondary alcohol metabolite formation in human or rabbit heart: biochemical aspects and pharmacologic implications.
Mordente A; Minotti G; Martorana GE; Silvestrini A; Giardina B; Meucci E
Biochem Pharmacol; 2003 Sep; 66(6):989-98. PubMed ID: 12963485
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model. II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin.
Salvatorelli E; Menna P; Gonzalez Paz O; Surapaneni S; Aukerman SL; Chello M; Covino E; Sung V; Minotti G
J Pharmacol Exp Ther; 2012 May; 341(2):474-83. PubMed ID: 22338034
[TBL] [Abstract][Full Text] [Related]
11. Human heart cytosolic reductases and anthracycline cardiotoxicity.
Mordente A; Meucci E; Martorana GE; Giardina B; Minotti G
IUBMB Life; 2001 Jul; 52(1-2):83-8. PubMed ID: 11795600
[TBL] [Abstract][Full Text] [Related]
12. 4'-Epidoxorubicin to re-explore anthracycline degradation in cardiomyocytes.
Menna P; Salvatorelli E; Minotti G
Chem Res Toxicol; 2009 Jun; 22(6):978-83. PubMed ID: 19397277
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of anthracycline cardiotoxicity with the model of isolated, perfused rat heart: comparison of new analogues versus doxorubicin.
Pouna P; Bonoron-Adèle S; Gouverneur G; Tariosse L; Besse P; Robert J
Cancer Chemother Pharmacol; 1995; 35(3):257-61. PubMed ID: 7805186
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin-dependent reduction of ferrylmyoglobin and inhibition of lipid peroxidation: implications for cardiotoxicity of anticancer anthracyclines.
Menna P; Salvatorelli E; Giampietro R; Liberi G; Teodori G; Calafiore AM; Minotti G
Chem Res Toxicol; 2002 Sep; 15(9):1179-89. PubMed ID: 12230412
[TBL] [Abstract][Full Text] [Related]
15. The role of biotransformation in anthracycline-induced cardiotoxicity in mice.
de Jong J; Schoofs PR; Snabilié AM; Bast A; van der Vijgh WJ
J Pharmacol Exp Ther; 1993 Sep; 266(3):1312-20. PubMed ID: 8371139
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Anthracycline Alcohol Metabolite Formation in Human Heart Cytosol: A Potential Role for Several Promising Drugs.
Mordente A; Silvestrini A; Martorana GE; Tavian D; Meucci E
Drug Metab Dispos; 2015 Nov; 43(11):1691-701. PubMed ID: 26265744
[TBL] [Abstract][Full Text] [Related]
17. Modeling Human Myocardium Exposure to Doxorubicin Defines the Risk of Heart Failure from Low-Dose Doxorubicin.
Salvatorelli E; Menna P; Chello M; Covino E; Minotti G
J Pharmacol Exp Ther; 2017 Aug; 362(2):263-270. PubMed ID: 28559479
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicinolone formation and efflux: a salvage pathway against epirubicin accumulation in human heart.
Salvatorelli E; Menna P; Lusini M; Covino E; Minotti G
J Pharmacol Exp Ther; 2009 Apr; 329(1):175-84. PubMed ID: 19144686
[TBL] [Abstract][Full Text] [Related]
19. In vitro modeling of the structure-activity determinants of anthracycline cardiotoxicity.
Menna P; Minotti G; Salvatorelli E
Cell Biol Toxicol; 2007 Jan; 23(1):49-62. PubMed ID: 17031515
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies.
Salvatorelli E; Menna P; Cascegna S; Liberi G; Calafiore AM; Gianni L; Minotti G
J Pharmacol Exp Ther; 2006 Jul; 318(1):424-33. PubMed ID: 16614166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]